BF Biosciences Ltd
Shariah compliantA strong balance sheet and the price in an uptrend. Priced above its peers.
Working
- Debt is 30% of equity in the latest quarter.
- Revenue up 14% on the same quarter last year.
- Short-term assets cover short-term bills 1.8 times in the latest quarter.
To watch
- P/E 18.6 against a sector median of 11.9.
- Free cash flow negative, Rs 864m out last year, after Rs 655m out the year before.
- Operating margin 12% over the last twelve months, below its average of 16% over the last 3 years.
Keep reading BFBIO: business, price trend and value
How good the business is, where its support zone sits, what it may be worth, its health, dividends, peers and latest results open with a free account.
Latest results
Quarter: Jul–Sep 2026In the Jul–Sep 2026 quarter, BFBIO's sales rose 14% to Rs 2.8bn, from Rs 2.4bn, and profit after tax rose 16% to Rs 184.9mn, from Rs 160.0mn (compared with Jul–Sep 2025).
Earnings per share were Rs 2.09, against Rs 1.81 a year earlier.
At Rs 138.24, BFBIO trades at 20.0 times earnings.
- P/E ratio
- 20.0
- Dividend yield
- 0.0%
- Dividend payout
- 0%
- of earnings
- Return on equity
- 12%
- Net margin
- 7.0%
- last 12 months
- Debt to equity
- 0.30
BFBIO quarterly results
Reported figures| Quarter | Sales | Profit after tax | Net margin | EPS | Dividend / share |
|---|---|---|---|---|---|
| Jul–Sep 2026 | Rs 2.8bn | Rs 184.9mn | 6.6% | Rs 2.09 | — |
| Apr–Jun 2026 | Rs 2.2bn | Rs 166.1mn | 7.5% | Rs 1.89 | — |
| Jan–Mar 2026 | Rs 2.1bn | Rs 118.0mn | 5.5% | Rs 1.33 | — |
| Oct–Dec 2025 | Rs 2.7bn | Rs 188.0mn | 7.0% | Rs 2.13 | — |
| Jul–Sep 2025 | Rs 2.4bn | Rs 160.0mn | 6.6% | Rs 1.81 | — |
| Apr–Jun 2025 | Rs 1.6bn | Rs 129.0mn | 7.9% | Rs 1.45 | — |
| Jan–Mar 2025 | Rs 1.5bn | Rs 125.0mn | 8.3% | Rs 1.40 | — |
| Oct–Dec 2024 | Rs 1.3bn | Rs 80.0mn | 6.0% | Rs 0.90 | — |
BFBIO annual results and dividends
Reported figures| Year | Sales | Profit after tax | EPS | Dividend / share |
|---|---|---|---|---|
| Year to Jun 2026 | Rs 9.5bn | Rs 632.1mn | Rs 7.16 | — |
| Year to Jun 2025 | Rs 5.8bn | Rs 447.0mn | Rs 5.52 | — |
| Year to Jun 2024 | Rs 3.7bn | Rs 386.0mn | Rs 6.09 | — |
| Year to Jun 2023 | Rs 1.8bn | Rs 150.0mn | Rs 2.35 | — |
Balance sheet and price
Balance sheet as of Sep 2026- Total assets
- Rs 9.7bn
- Shareholders' equity
- Rs 5.5bn
- Cash & bank
- Rs 178.3mn
- Total debt
- Rs 1.7bn
- Current ratio
- 1.81
- 3-month high
- Rs 138.24
- 3-month low
- Rs 119.97
- 1-month change
- +10.1%
- 3-month change
- +1.7%
Read more about BFBIO
Other pharmaceuticals companies
- ABOTAbbot Laboratories (Pakistan) LtdRs 924.15P/E 11.1
- AGPAGP LtdRs 149.85P/E 12.7
- CPHLCiti Pharma LtdRs 63.42P/E 15.7
- CWHCCrestwell Healthcare LimitedRs 21.35
- FEROZFerozsons Laboratories LtdRs 337.68P/E 16.4
- GLAXOGlaxoSmithKline Pakistan LtdRs 315.00P/E 10.4
- HALEONHaleon Pakistan LtdRs 658.64P/E 12.7
- HINOONHighnoon Laboratories LtdRs 956.76P/E 12.1
- HPLHoehcst Pakistan LtdRs 4056.91P/E 10.4
- IBLHLIBL HealthCare LtdRs 39.86P/E 19.1
- LIVENLiven Pharma LimitedRs 31.47
- MACTERMacter International LtdRs 244.00P/E 15.3
BFBIO: common questions
What is BFBIO's share price?
BF Biosciences Ltd (BFBIO) last closed at Rs 138.24 on the Pakistan Stock Exchange.
Does BFBIO pay a dividend?
BF Biosciences Ltd reported no dividend for the year to Jun 2026.
What were BFBIO's latest results?
In the Jul–Sep 2026 quarter, BFBIO's sales rose 14% to Rs 2.8bn, from Rs 2.4bn, and profit after tax rose 16% to Rs 184.9mn, from Rs 160.0mn (compared with Jul–Sep 2025).
What is BFBIO's P/E ratio?
At Rs 138.24, BFBIO trades at 20.0 times its earnings.
Figures are taken from the company's published financial statements and PSX prices. This page is information, not investment advice.

